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Abstract
Objectives
To evaluate the impact of preoperative anemia and perioperative blood transfusion (PBT)
on disease free (DFS) and overall survival (OS) of patients with head and neck squamous
cell carcinoma (HNSCC).
Methods
Retrospective study of 354 patients primarily treated with surgery between 2006 and 2016.
Cases were selected according to completeness and accuracy of available clinical data.
Thus, a selection bias cannot be excluded. Patients who received PBT were identified by
our controlling department and verified by our blood bank data base.
Results
Both, preoperative anemia and PBT significantly decreased OS in univariate analysis.
Although PBT was needed more frequently by older patients in worse physical conditions
with more advanced HNSCC, subgroup analysis also demonstrate a profoundly negative
effect of PBT on OS in younger patients and early stage HNSCC. According to a restrictive
transfusion policy at our hospital the transfusion rate was comparably low. We could not ver-
ify increasing effects of PBT on cancer recurrence rates as it was previously shown.
Discussion
Preoperative anemia is the most common paraneoplastic syndrome in HNSCC. Despite its
devastating prognostic effect we suggest a restrictive transfusion policy whenever possible.
Our data also show that anemia as an independent prognostic factor in head and neck surgi-
cal oncology is defined not only by low hemoglobin concentrations but low red blood cell
counts as well.
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Introduction
There is an increasing awareness of the negative effects of blood products in cancer treatment
[1]. Once considered as a benign intervention, perioperative blood transfusion (PBT) is nowa-
days recognized as a measure that should be avoided if possible. Seemingly purified products
like red blood cell (RBC) suspensions contain variable contents of other blood cells and biolog-
ically active compounds [2, 3]. Several processes that occur during and after transfusion are
discussed as causes for its adverse effects in surgical oncology. As reviewed by Cata et al., these
mechanisms include immunosuppression induced by and inflammatory response to PBT.
Before routine depletion of leucocytes, post-transfusion infections and febrile reactions were
common adverse events [4]. By leucoreduction, the release of bioactive substances from white
blood cells can largely be avoided. Nevertheless, several actives cytokines are still present in
stored erythrocyte units [5]. Units of red blood cells also contain lipids and a variety of pro-
inflammatory mediators like phosphatidylcholines and eicosanoids, as well as microparticles
containing numerous growth factors [6, 7, 8]. The immunomodulatory effects of allogeneic
blood transfusions include a decrease of interleukin 2 secretion, a diminished activity of natu-
ral killer cells and macrophages, as well as hypersensitivity reaction. PBT can undoubtedly save
lifes. On the other hand, mounting evidence shows that it negatively affects patient‘s immune
surveillance of cancer and promotes tumor growth and dissemination [4, 8].
Numerous systematic reviews and meta-analyses prove the adverse influence of PBT on
outcomes in literally all solid cancers including cholangiocarcinoma, liver, bladder, pancreatic,
gastric and lung cancer [9–14]. However, much less is known about PBT‘s role in head and
neck squamous cell carcinoma (HNSCC). In contrast to, for example, hepatectomy, intra- and
perioperative blood transfusions are relatively rare events in the surgical treatment of HNSCC.
Still, preoperative anemia is common among HNSCC patients. Anemic conditions before
treatment may be attributed to the disease itself, impaired dietary intake and comorbid condi-
tions of HNSCC patients [15–17].
We recently described the negative impact of anemia on prognosis of oropharyngeal cancer
patients [18]. In this localization two distinct HNSCC entities need to be distinguished. On
one hand there are “classic” carcinomas linked to tobacco and alcohol consumption and with
a peak onset within the 6th decade of life. Affected patients often show a variety of comorbid
diseases associated with the respective noxious agents and age. On the other hand an increas-
ing number of oropharyngeal carcinomas are caused by a persistent infection with high-risk
human papilloma viruses (HPV). Affected patients are often younger, have no or a limited
smoking history and, therefore, less comorbid diseases. Clinically, HPV-associated HNSCC in
the oropharynx are identified by positive immunohistochemical staining of p16, a cell cycle
regulator that accumulates within cancer cells in the course of HPV-driven carcinogenesis.
Despite being less differentiated and showing more advanced cervical lymph node metastasis,
HPV-/p16-positive HNSCC are characterized by a remarkably improved therapeutic response
and patient‘s survival. Less exposure to tobacco-contained carcinogens, less genetic mutations
and better overall health are discussed as major contributors to favorable prognosis. Distinct
etiology, tumor biology and therapeutic response led to the acknowledgement of p16-positive
oropharyngeal squamous cell carcinomas as a discrete cancer entity in the head and neck with
a separate clinical staging system valid since January 2017 [19, 20]
For this study we extended the cohort and included patients who received PBT during their
stay at our department. The aim of the study was to confirm our previous results regarding the
prognostic effects of anemia in HNSCC and to evaluate the impact of PBT on survival in these
patients.
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Methods
We retrospectively included 354 patients who underwent surgical resection of their HNSCC at
the Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-Uni-
versity (LMU), Munich, between January 2006 and October 2016. For this period we obtained
a list of patients from our controlling department who were administered blood products.
This list was then matched with our blood bank to identify patients who received PBT. All clin-
ical data was obtained from paper based and digital patient files. Follow up data was recorded
during posttherapeutic visits and from The Munich Cancer Registry. Clinical data was initially
collected without involving the ethics committee, LMU, Munich. After subsequent consulta-
tion, the committee stated that patients are not required to sign an informed consent and
endorses the publication of the manuscript. A minimal, fully anonymized set of clinical data is
available as supporting information.
The World Health Organization (WHO) defines anemia as “a condition in which the num-
ber of red blood cells or their oxygen-carrying capacity is insufficient to meet physiologic needs,
which vary by age, sex, altitude, smoking, and pregnancy status” (http://www.who.int/topics/
anaemia/en/). The WHOGlobal Database on Anemia reports on the worldwide prevalence of
anemia based on hemoglobin concentration. We used both, red blood cell counts (RBC) and
hemoglobin-concentration to define anemic conditions as:
1) RBC <4.3T/l in women and<4.8T/l in men, and/or
2) hemoglobin-concentration<12 g/dL in women and <14 g/dL in men
Although the WHO uses a worldwide threshold of 13 g/dL for men>15 years of age below
which the individual is considered to be anemic, the medical center of Ludwig-Maximilians-
University Munich applies the local population based threshold of 14 g/dl for adult men [21].
The hemoglobin threshold that triggers blood transfusion in head and neck surgical oncology
is 7 g/dl unless comorbid diseases require other measures. Therefore, our clinic pursues a
restrictive transfusion policy [22].
Erythrocytes concentrates transfused within the observation time were obtained from the
Bavarian Red Cross, Munich, Germany or from the Institute for Transfusion Medicine, Suhl,
Germany. The major additive during a maximum storage period of 49 days was mannitol. All
erythrocyte concentrates/units of packed red blood cells underwent leucocyte depletion before
storage.
The perioperative period was defined as the timespan between inpatient admission before
surgery and discharge from our department. Disease free survival was defined as the time span
between surgery and disease recurrence (local and/or regional and/or distant, as well as second
primary carcinomas) or death of any cause. Overall survival was defined as the period of time
between cancer resection and death of any cause.
Statistical analysis was performed using IBM SPSS Statistics, version 24. p-level was set to
0.05. To test relations between nominal and ordinal scaled factor, the chi square test was
applied. Metric scaled variables were tested using the Mann-Whitney-U test. Survival estimates
were produced with the Kaplan-Meier method. Significant differences were calculated using
log rank test in univariate and cox regression for multivariate analysis. The number of vari-
ables included for multivariate analysis were restricted to 1 per 10 events. For this purpose we
selected the most significant factors in univariate analysis.
For manuscript writing we tried to adhere to The Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational stud-
ies [23].
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Results
354 cases were included. Patient and tumor data are summarized in Table 1. All patients
underwent surgical resection of their carcinoma with or without free flap reconstruction, 343
received uni- or bilateral neck dissection. 258 patients were treated with adjuvant (chemo)
radiotherapy following surgery. To avoid bias regarding intraoperative blood loss, we excluded
tumor resection carried out with lasermicrosurgery. Thus, only total laryngectomies were
included.
In accordance to what is currently known about p16-negative and -positive HNSCC, all 71
p16-positive tumors were located in the oropharynx. Patients with p16-positive tumors were
less often current smokers (30.9% vs. 65.9%; p<0.001). p16-positive cancers were less differen-
tiated (G3: 83.1% vs. 54.0%; p<0.001) and had more often spread to cervical lymph nodes (pN
+: 84.5% vs. 61.4%; p = 0.001). No difference between p16-positive and -negative cases was
found regarding age and preoperative assessment of physical status according to the American
Society of Anesthesiologists (ASA).
Anemia
Preoperative blood samples were taken at least 10 days before surgery. Mean RBC was 4.50 T/l
(median: 4.53; range: 2.32–5.81), mean hemoglobin concentration 13.99 g/dl (median: 14.2;
range: 8.0–17.8). A total of 154 patients (43.5%) were found to be anemic. 70 patients had low
hemoglobin level and low RBC counts. 9 patients had low hemoglobin concentrations, but
normal RBC counts. 75 patients were classified as anemic because of low RBC counts only.
Anemic conditions were independent from gender, age, ASA-classification, pathological
tumor (pT-), pathological lymph node (pN-) stage and prognostic stage group as defined by
the Union Internationale Contre le Cancre (UICC). Current (49.7%) or former smokers
(41.6%) at the time of diagnosis were more often anemic compared to never smokers (25.3%;
p = 0.001). Hence, patients diagnosed with HPV-associated, p16-positive HNSCC suffered less
often from anemic conditions than p16-negative cases (26.8% vs. 60.9%; p<0.001).
Perioperative blood transfusion (PBT)
65 patients (18.4%) received at least one PBT. In 24 of these cases (36.9%) a postoperatively
developing or increasing anemia without any apparent cause was corrected. 23 patients
(35.4%) received PBT during initial tumor resection or during revision surgery. In 12 cases
(18.5%) at least one erythrocyte concentrate was transfused in response to postoperative bleed-
ing. 6 patients (9.2%) needed blood transfusion(s) in the course of measures unrelated to the
tumor resection. For instance, two patients suffered a postoperative myocardial infarction and
needed PBT to support coronary perfusion. One patient received a total of 45 erythrocytes
transfusions in the course of a fulminant deep vein thrombosis that finally led to leg amputa-
tion. A total of 11 patients received platelet concentrates only (1 patient), fresh frozen plasma
only (5 patients), or a combination of both (5 patients) in addition to erythrocyte concentrates.
56.9% of transfused patients received 1–2 erythrocyte concentrates, the median amount was
2.0 units per patient (range: 1–45; average: 4.9).
The need for PBT was independent from gender. Patients who received PBT were older
(62.6 vs. 59.7 years; p = 0.021) and in worse physical condition. Whereas only 4.1% of patients
classified as ASA1/2 were given PBT, this rate was 31.7% in ASA3/4-patients (p<0.001). No
correlation was found with smoking habits. PBT was given less often to preoperatively non-
anemic patients (10.5% vs. 28.6%; p<0.001) and more often to patients with p16-negative
HNSCC (33.3% vs. 16.9%; p = 0.019). Furthermore, patients with advanced pT- and pN-stages
received more frequently PBT (pT1-2 vs. pT3-4a: 12.9% vs. 29.8%; p<0.001; pN0-pN2b vs.
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Table 1. Clinical data.
n (%)
Preoperative anemia yes 154 (43.5%)
no 200 (56.5%)
Perioperative blood transfusion yes 65 (18.4%)
no 289 (81.6%)
Age <60 171 (48.3%)
�60 183 (51.7%)
ASA (physical status) ASA1 19 (5.4%)
ASA2 152 (42.9%)
ASA3 179 (50.6%)
ASA4 1 (0.3%)
N/A 3 (0.8%)
Smoking current 187 (52.8%)
former 77 (21.8%)
never 75 (21.2%)
N/A 15 (4.2%)
Localization oral cavity 93 (26.3%)
oropharynx 221 (62.4%)
hypopharynx 34 (9.6%)
larynx 6 (1.7%)
pT-stage1 pT1 95 (26.8%)
pT2 145 (41.0%9
pT3 90 (25.4%)
pT4a 24 (6.8%)
pN-stage1 pN0 126 (35.6%)
pN1 55 (15.5%)
pN2a 28 (7.9%)
pN2b 80 (22.6%)
pN2c 49 (13.8%)
pN3 5 (1.4%)
pNx 11 (3.1%)
UICC-stage1 I 47 (13.3%)
II 53 (15.0%)
III 97 (27.4%)
IVA 141 (39.8%)
IVB 4 (1.4%)
N/A 11 (3.1%)
p16 positive 71 (20.1%)
negative 87 (24.6%)
N/A 201 (55.4%)
Perineural invasion Pn0 (absent) 106 (29.9%)
Pn1 (present) 33 (9.3%)
N/A 139 (39.3%)
Lymphovascular invasion L0 (absent) 113 (31.9%)
L1 (present) 68 (19.2%)
N/A 173 (48.9%)
Vein invasion V0 (absent) 166 (46.9%)
V1 (present) 12 (3.4%)
(Continued)
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pN2c-pN3: 14.5% vs. 25.9%; p = 0.038). Transfusion rate was, thus, 7.0% for UICC-stage I /II-
and 20.2% in UICC-stage III-IVb-patients (p = 0.001).
Survival analysis
All factors shown in Table 1 were submitted to uni- and multivariate analysis of disease free
(DFS) and overall survival (OS; Table 2). We recorded 128 recurrences, 126 patients died.
Thus, factors included in multivariate analysis of DFS and OS were restricted to 13 (1 variable
per 10 events).
Even though preoperative anemia influenced DFS, there were more significant factors in
univariate analysis. In multivariate analysis only pT-stage remained significant. Both, preoper-
ative anemia and PBT were highly significant for OS in univariate analysis. Also, pN-stage and
perineural invasion showed comparable significance. Whereas pretreatment anemia and PBT
lost significance in multivariate analysis, perineural invasion emerged as the most significant
factor for OS.
To emphasize the effects of preoperative anemia and PBT we build four classes (Fig 1):
A. Preoperatively non-anemic patients, no transfusion (n = 179)
B. Preoperative non-anemic patients, perioperative transfusion (n = 21)
C. Preoperative anemic patients, no transfusion (n = 110)
D. Preoperative anemic patients, perioperative transfusion (n = 44)
Preoperatively non-anemic patients had a significantly better OS compared to non-anemic
patients who received PBT (A vs B, p = 0.0179), to anemic patients without PBT (A vs C,
p = 0.002) and to anemic patients who needed PBT (A vs D, p<0.001). No statistical difference
in OS was found between transfused non-anemic patients and anemic patients without PBT
(B vs C, p = 0.687) and transfused anemic patients (B vs. D, p = 0,189), respectively. Moreover,
anemic patients who received PBT had a significantly worse OS compared to anemic patients
who were not transfused (C vs. D, p = 0.021).
Table 1. (Continued)
n (%)
N/A 176 (59.7%)
Extranodal extension ENE- 63 (17.8%)
ENE+ 58 (16.4%)
N02 126 (35.6%)
N/A 107 (30.2%)
Grading G1 24 (6.8%)
G2 134 (37.9%)
G3 196 (55.4%)
Adjuvant treatment yes 258 (72.9%)
no 95 (26.8%)
N/A 1 (0.3%)
1 Union International contre le Cancre (UICC), Staging Manual, 7th edition;
2 clinically or pathologically N0
https://doi.org/10.1371/journal.pone.0205712.t001
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As stated before, PBT was more frequently administered to older patients, patients in worse
physical conditions, anemic patients, patients with p16-negative HNSCC and patients with
more advanced pT- and pN-stage HNSCC. Because all these factors are major determinants of
OS, we did an analysis of the influence of PBT on OS in 6 subgroups: In patients <60 years of
age, in patients classified as ASA1 or 2, in non-anemic patients, in patients with p16-positive
HNSCC and in patients with pT1-2 and pN0-2b HNSCC, respectively. Aside from ASA1 &
2-patients PBT led to a significantly worse survival in all these subgroups (Table 3).
OS depending on hemoglobin and RBC status is shown in a separated figure (Fig 2).
Table 2. Survival analysis (entire cohort).
Disease free survival
univariate
(log rank test)
multivariate
(cox regression)
n/censored p p
Preoperative anemia 354/226 0.043 0.792
Perioperative blood transfusion 354/226 0.137 0.496
Age 354/226 0.182 0.427
ASA 351/225 0.297 0.619
Smoking 339/217 0.628 -
Localization 354/226 0.002 0.055
pT-stage 354/226 0.059 0.029
pN-stage 343/223 0.033 0.566
UICC 343/223 0.825 -
p16 158/118 0.016 0.525
Perineural invasion 139/105 0.002 0.124
Lymphovascular invasion 181/134 0.438 0.365
Vein invasion 178/131 0.358 0.561
Extranodal extension 121/89 0.077 0.588
Grading 354/226 0.816 -
Adjuvant treatment 353/225 0.032 0.957
Overall survival
univariate (log rank test) multivariate (cox regression)
n/censored p p
Preoperative anemia 354/226 <0.001 0.663
Perioperative blood transfusion 354/226 <0.001 0.363
Age 354/226 0.001 0.296
ASA 351/225 0.027 0.778
Smoking 339/217 0.155 0.422
Localization 354/226 0.007 0.014
pT-stage 354/226 0.102 0.952
pN-stage 343/223 <0.001 0.598
UICC 343/223 0.041 0.449
p16 158/118 0.006 0.404
Perineural invasion 139/105 <0.001 0.009
Lymphovascular invasion 181/134 0.112 -
Vein invasion 178/131 0.019 0.859
Extranodal extension 121/89 0.078 0.330
Grading 354/226 0.985 -
Adjuvant treatment 353/225 0.240 -
https://doi.org/10.1371/journal.pone.0205712.t002
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Discussion
Approximately 40% of all cancer patients are anemic at diagnosis. Hence, anemia is the most
common paraneoplastic syndrome. The causes of anemia in cancer include tumor-triggered
formation of antibodies leading to autoimmune hemolysis. Antibodies may also suppress eryth-
ropoietin-induced RBC production causing pure red-cell aplasia. In some advanced malignan-
cies physically injured erythrocytes, as a consequence of vascular damage and activation of
coagulation by the tumor, die prematurely, causing microangiopathic hemolytic anemia. The
commonest type of cancer-associated anemia and anemic conditions caused by other chronic
diseases is defined by impaired iron metabolism. As a consequence of the increased expression
Fig 1. Kaplan-Meier-plots of overall survival of: A: preoperatively non-anemic, not transfused patients. B:
preoperatively non-anemic, transfused patients. C: preoperatively anemic, not transfused patients. D: preoperatively
anemic, transfused patients.
https://doi.org/10.1371/journal.pone.0205712.g001
Table 3. Overall survival (OS) in subgroups.
Subgroup PBT OS (95% CI) [years] p (log rank test)
Age < 60 no 7.03 (6.25–7.81) <0.001
yes 2.98 (1.71–4.24)
ASA1 & 2 no 6.93 (6.22–7.64) 0.365
yes 5.01 (2.55–7.48)
Normemic patients no 7.35)6.64–8.07) 0.017
yes 4.16 (2.95–5.38)
p16-positive HNSCC no 6.04 (5.47–6.62) 0.042
yes 3.80 (2.71–4.89)
pT1 & 2 no 6.93 (6.27–7.59) <0.001
yes 3.31 (2.36–4.26)
pN0-2a no 6.97 (6.36–7.59) 0.029
yes 4.23 (3.29–5.17)
https://doi.org/10.1371/journal.pone.0205712.t003
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of hepcidin, a type II acute-phase reactant, intestinal iron absorption and iron release from mac-
rophages is downregulated. This leads to a functional iron deficiency that worsens low nutri-
tional iron intake often seen in HNSCC patients [24–26]. Tobacco consumption, still the
leading cause of carcinogenesis in the head and neck and comorbid diseases in HNSCC pat-
ients, may initially counterbalance paraneoplastic anemia due to the effects of chronic carbon
monoxide exposure, but cigarette smoke is also linked to hemolysis, aplastic anemias and hema-
totoxicity itself [16]. As reported previously, the impact of smoking on anemia in HNSCC
patients, can be demonstrated comparing patients diagnosed with p16-negative to patients suf-
fering from p16-positive oropharyngeal carcinomas. Significantly less tobacco consumption in
the latter group leads to significantly less comorbidities and, thus, to significantly less anemic
conditions [18]. Accordingly, these patients are less likely to receive PBT.
Anemia is an independent prognostic factor in various solid malignancies. It was found to
have an exceptionally pervasive effect in head and neck carcinomas and to lead to a relative
risk of death increased by 75% compared to non-anemic cancer patients [27]. It was recently
shown that preoperatively low hemoglobin levels decrease OS in a study of 167 head and neck
cancer patients undergoing tumor resection followed by free flap reconstruction between July
2007 and February 2013 [28]. As demonstrated by Chau et al., preoperative hemoglobin con-
centrations <12 g/dL increased recurrence rates and survival in a retrospective study of 520
patients who underwent primary resection of various head and neck malignancies [29].
The existence of far-reaching effects of blood transfusion on the immune system is no lon-
ger subject of discussion. The condition termed transfusion-related immune modulation is
well established in transfusion medicine and its immunosuppressive component was once
therapeutically exploited to reduce allograft rejection after kidney transplantation [4, 30]. This
very effect is suspected to increase the risk of disease recurrence and decreased survival in sur-
gical oncology. Accordingly, PBT was shown to be associated with higher recurrence rates and
decreased survival in head and neck cancer. Taniguchi et al. retrospectively analyzed 105
patients with stage III and IVa oral cavity squamous cell carcinomas who underwent tumor
Fig 2. Kaplan-Meier-plots of overall survival depending on hemoglobin-levels and red blood cell (RBC)-counts.
https://doi.org/10.1371/journal.pone.0205712.g002
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resection and neck dissection between January 1990 and December 1998. Overall survival of
patients who received�3 units was significantly lower [31]. This finding was later confirmed
by Szakmany et al. in a study of 559 patients with oral cavity and oropharyngeal squamous cell
carcinomas undergoing primary surgery between 1992 and 2002 [32]. Danan and colleagues
also supported the threshold of�3 units of packed red blood cells transfusion. Patients who
received this amount had a significantly increased risk of death [28]. In the study by Chau and
colleagues, PBT was associated not only decreased survival but also with higher recurrence
rates [29]. The results of the latter studies were opposed by Fenner and colleagues who retro-
spectively analyzed the cases of 223 patients with oral squamous cell carcinoma undergoing
primary surgery between July 1998 and June 2002. According to their results, transfusion of
>4 units of packed red blood cells did not influence overall survival [33].
Interestingly, transfusion rates vastly differed between these studies. While Taniguchi and
colleagues report that 61.0% of their patients received one or more PBT [31], this rate was
77.1% [32], 82.0% [28], 37.9% [29] and 97.3% [33] in other studies cited.
In our study both, peroperative anemia and PBT had little impact on DFS. In contrast, both
factors significantly decreased OS in univariate analysis, even though tumor localization and
perineural invasion of cancer cells emerged as most significant in multivariate analysis
(Table 2). These results lead to the question whether the administration of PBT increased mor-
tality, or whether patients who received PBT were more likely to decease anyway. Because in
our study PBT was more frequently needed by older patients, patients in worse physical condi-
tions, anemic patients, patients with p16-negative and more advanced pT- and pN-stage
HNSCC, we suggest that these factors contributed to the significance of PBT in univariate
analysis of OS. Also, patients who received PBT died significantly more often of cancer-unre-
lated causes (38.9% vs. 28.1%; p = 0.031). Nevertheless, subgroup analyses revealed the pro-
found negative impact of PBT on OS in patients <60 years of age, non-anemic patients,
patients with p16-postive HNSCC and early pT- and pN-stage carcinomas, too (Table 3).
Notably, subgroup analyses cannot be interpreted as a substitute of multivariate analyses.
There is an ongoing discussion regarding adequate triggers for red blood cells transfusion.
Two major transfusion strategies can be discerned. According to the liberal transfusion policy,
the threshold hemoglobin concentration is 9–10 g/dL. The restrictive transfusion strategy‘s
threshold is 7–8 g/dL [22]. In a recent review for the Cochrane collaboration, Carson and col-
leagues conclude that there is good evidence that transfusions with allogeneic red blood cells
can be avoided in most hospitalized patients with hemoglobin concentrations above 7 g/dL to
8 g/dL [34]. The policy of both, the Department of Anesthesiology and the Department of
Otorhinolaryngology, Head and Neck Surgery in our clinic is to avoid PBT for head and neck
cancer patients until a threshold of<7 g/dL is reached. Thus, different transfusion strategies
are most likely the reason for vastly differing transfusion rates. Our cohort had the lowest
transfusion rate of all studies cited. Because of the retrospective design of this study a selection
bias cannot be excluded, but the calculated transfusion rate of 18.4% corresponds with the clin-
ical experience of the authors.
The WHO defines anemia primarily as insufficient number of red blood cells. Applying
this very definition of anemia, not only low hemoglobin concentrations as a surrogate for oxy-
gen-carrying capacity, almost as many patients (75) were classified anemic as were found to be
anemic according to hemoglobin levels (79). Patients classified anemic based on RBC only
show a significantly worse survival compared to non-anemic patients (p<0.001; Fig 2). The
vast majority of clinical studies on the impact of anemia in HNSCC are based on hemoglobin
concentrations [28, 29, 35–37]. Therefore, an important finding of our study is that anemia as
an independent prognostic factor in surgical oncology of the head and neck should be defined
as low hemoglobin concentration as well as low RBC.
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Summary
Anemic conditions of HNSCC patients are a common paraneoplastic syndrome of various
causes. Unlike all other factors analyzed for their impact on survival in this study, pre- and
perioperative anemia is a potential aim of therapeutic intervention. Even though in our study,
perioperative blood transfusion was needed more frequently by older patients in worse physi-
cal condition suffering from more advanced stage HNSCC, subgroup analyses demonstrate
the negative impact of PBT in younger patients with early stage HNSCC, too. Therefore, we
conclude that a restrictive transfusion policy is appropriate in surgical oncology of HNSCC.
Despite the devastating impact of anemia in HNSCC, we suggest that anesthesiologists and
surgeons should restrain from correcting anemic conditions by PBT unless urgently needed.
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